Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy. Treatment-naïve patients with PNH show
NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation Cambridge, UK, 25 June 2018 – NodThera,
Edinburgh, Scotland, 21st June 2018 – AdoRx Therapeutics, a UK based drug discovery company focused on the identification of new cancer therapeutics, today announced that
£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM to progress second product candidate towards the clinic London, 9 May 2018 – IGEM
Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
Interim data shows broad hematologic correction including improved hemoglobin levels and reduction in LDH CRESTWOOD, KY. and WALTHAM, MA., April 16, 2018 (GLOBE NEWSWIRE) —
Initially founded with capital from leading healthcare investor Epidarex Capital, Enterprise raises Series B round co-led by Versant Ventures and Novartis Venture Fund, with Forbion,
Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate
March 26, 2018 – Mironid is delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board Prof. Dr. Dorien Peters is